Lipoprotein (a)
Genetic cardiovascular risk factor
13 of 22 providers
Lipid Panel / Cardiovascular Health
Desirable:<30 mg/dL, Borderline:30-50 mg/dL, High:>50 mg/dL
What is Lipoprotein (a)?
Lipoprotein (a), abbreviated as Lp(a), is a unique cholesterol particle consisting of an LDL-like particle with an additional protein called apolipoprotein(a) attached to it. Often called "the forgotten cholesterol,"Lp(a) is a powerful independent risk factor for cardiovascular disease, stroke, and aortic valve stenosis. What makes Lp(a) particularly challenging is that your levels are 70-90% genetically determined and largely unresponsive to diet and lifestyle changes.
Lp(a) is highly atherogenic and prothrombotic, meaning it both promotes plaque formation and increases blood clotting tendency. The apolipoprotein(a) component has structural similarity to plasminogen, interfering with the body's clot-dissolving mechanisms. Lp(a) particles are smaller and more easily oxidized than regular LDL, making them particularly damaging to arterial walls. Approximately 20-30% of the population has elevated Lp(a) levels, often without knowing it.
Despite being discovered in 1963, Lp(a) has only recently gained widespread clinical attention as a critical cardiovascular risk factor. Elevated Lp(a) can explain premature heart disease in people with otherwise healthy lipid profiles and may account for much of the "residual risk"in statin-treated patients. Major cardiology societies now recommend at least one Lp(a) measurement in every adult's lifetime for risk stratification, as knowing your Lp(a) level can significantly impact cardiovascular prevention strategies.
Why Lipoprotein (a) Is Essential
- Independent genetic risk factor for cardiovascular disease
Optimal vs Standard Ranges
Optimal<30 mg/dL or <75 nmol/L▼
Low cardiovascular and thrombotic risk.
Borderline30-50 mg/dL or 75-125 nmol/L▼
Moderately elevated;warrants attention to other CVD risk factors.
Very Low<10 mg/dL▼
Very low Lp(a) is not clinically concerning and may be protective.
High Risk>50 mg/dL or >125 nmol/L▼
- Significantly increased CVD risk
- Genetically determined, limited treatment options
Scientific Evidence
PCSK9 Inhibitors and Lp(a) Reduction
Clinical trials showing that PCSK9 inhibitors reduce Lp(a) by 20-30% and that this reduction may contribute to cardiovascular benefit, suggesting therapeutic value even with modest Lp(a) lowering.
Lp(a) Screening Recommendations
Expert consensus statement from major cardiology societies recommending at least one Lp(a) measurement in all adults for cardiovascular risk stratification, particularly those with premature CVD or strong family history.
Source:Wilson et al., "Use of Lipoprotein(a) in Clinical Practice,"Circulation, 2019 (PubMed)
Novel Lp(a) Therapies
Phase 2 trial results demonstrating that antisense oligonucleotide therapy targeting Lp(a) production reduces levels by up to 90%, with phase 3 outcomes trials underway to determine cardiovascular benefits.
Source:
Which Providers Test Lipoprotein (a)?
Full Provider Comparison
| Provider | Includes | Annual Cost | Biomarkers |
|---|---|---|---|
 Superpower | ✓ | $199 | 100+ (150 with ratios) |
 WHOOP Advanced Labs | ✓ | $349 | 65 |
 Labcorp OnDemand | — | $398 | 30+ |
| — | $486 | 40+ | |
| — | $444 | 288 | |
| ✓ | $349 | 100+ | |
| — | $761 | 54 | |
 Function Health | ✓ | $365 | 160+ |
| — | $250 | 65 | |
| — | $495 | 70+ | |
| ✓ | $895 | 100+ | |
| ✓ | $1950 | 150+ | |
| ✓ | $375 | 80+ | |
| — | $Varies | 75+ | |
| ✓ | $190 | 100+ | |
| ✓ | $99 | 50 | |
| ✓ | $124 | 60 | |
| — | $199 | 50 | |
| ✓ | $499 | 120+ | |
| ✓ | $4188 | 70-80+ | |
| — | $375 | 85 | |
| ✓ | $700 | 128 |
Frequently Asked Questions
What is Lipoprotein (a)?
Genetic cardiovascular risk factor
What is the optimal range for Lipoprotein (a)?
The standard reference range for Lipoprotein (a) is Desirable:<30 mg/dL, Borderline:30-50 mg/dL, High:>50 mg/dL. Optimal ranges may differ based on individual health goals and expert recommendations.
Which blood test providers include Lipoprotein (a)?
13 out of 22 blood testing providers include Lipoprotein (a) in their panels. This biomarker is widely available across major providers.
What category does Lipoprotein (a) fall under?
Lipoprotein (a) is categorized under Lipid Panel / Cardiovascular Health. This category includes biomarkers that help assess related aspects of health and wellness.
Medical Disclaimer
This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider about your specific health needs.
Last reviewed:2026-02-20